Journal of diabetes investigation
-
J Diabetes Investig · May 2019
Observational StudyDiscordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus.
We aimed to investigate whether there are differences in the risk factors or markers for the progression of diabetic retinopathy (DR) and diabetic nephropathy (DN) in type 2 diabetes mellitus. ⋯ Average glycemia was significantly associated with progression of DR, whereas glycemic variability and dyslipidemia were significantly associated with progression of DN in type 2 diabetes mellitus.
-
J Diabetes Investig · Mar 2019
Randomized Controlled Trial Multicenter StudyAldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Diabetic polyneuropathy is one of the most frequent diabetic complications, and impairs patients' quality of life. We evaluated the efficacy and safety of ranirestat (40 mg/day) in patients with diabetic polyneuropathy. ⋯ Ranirestat (40 mg/day) was well tolerated and improved nerve conduction velocity. Regarding symptoms and signs, no detectable benefits over the placebo were observed in the ranirestat group during the 52 weeks of treatment.
-
J Diabetes Investig · Mar 2019
Randomized Controlled Trial Comparative Study Clinical TrialEffects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease. ⋯ Compared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Reductions in weight, fat mass and waist circumference favorably affect hepatic function.
-
J Diabetes Investig · Jan 2019
Contribution and interaction of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and triglyceride to diabetes in hypertensive patients: A cross-sectional study.
Hypertension is one of the most significant risk factors for diabetes. The present study aimed to investigate the associations of lipid profiles, including the ratio of low-density lipoprotein cholesterol (LDL-C)-to-high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels, as well as their interactions, with type 2 diabetes in hypertensive patients. ⋯ In conclusion, elevated LDL-C/HDL-C ratios and TG levels were associated with diabetes in patients with hypertension, with an interactive effect of the LDL-C/HDL-C ratio and TG on diabetes in the hypertensive population.
-
J Diabetes Investig · Jul 2018
Comment LetterDisease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.
Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).